In this newly created role, which will report directly to the CEO, Smith will lead the company’s global commercialization efforts, with a focus on both strategic and tactical execution efforts in sales, upstream and downstream marketing, field clinical support and training with a focus on adoption and clinical excellence.
“We are very excited to have Eric join the TransEnterix team. He brings a wealth of experience commercializing innovative technologies on a global scale,” CEO Todd M. Pope said. “As we look to drive widespread adoption of Senhance, we believe that the addition of Eric’s expertise in developing and driving sales and marketing strategies will complement our existing team as we continue to grow and increase our presence in the United States and around the world.”
Smith brings over two decades of medical technology experience to TransEnterix, with over a decade of that focused on commercial leadership and marketing strategy. Most recently, he was a vice president, franchise leader of Acute Care at KCI Corporation, a developer and manufacturer of wound healing products. While at KCI, he was responsible for the development and commercialization of innovative wound-care technologies on a global scale. Prior to joining KCI, Smith served as vice president of Global Strategic Marketing at Cordis Corporation, a developer and manufacturer of medical devices for the treatment of coronary and peripheral vascular diseases. He has also held senior positions at Boston Scientific Corp., C.R. Bard and Ernst & Young.
Smith received his bachelor’s degree from the University of New Hampshire and his MBA from Babson College.
“I am extremely pleased to be joining TransEnterix during such an exciting time in the company’s history,” said Smith. “Senhance is a transformative technology with a large market opportunity, and I look forward to contributing to the company’s success and improving clinical outcomes and patient care through the use of digital laparoscopy.”
TransEnterix is digitizing the interface between the surgeon and the patient to improve minimally invasive surgery by addressing the clinical and economic challenges associated with current laparoscopic and robotic options in today's value-based healthcare environment. The company is focused on the commercialization of the Senhance Surgical System, which digitizes laparoscopic minimally invasive surgery. The system allows for robotic precision, haptic feedback, surgeon camera control via eye sensing and improved ergonomics while offering responsible economics. The Senhance Surgical System is available for sale in the United States, the European Union, and select other countries.